Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

252
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
252
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

425
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
425
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

269
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
269
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

428
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
428
Pericarditis I: Introduction01:22

Pericarditis I: Introduction

264
Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
264
Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

1.9K
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cigarette Smoke Extract Exposure Affects Innate Immune Response, Metabolic Rate, and Locomotor Activity of Drosophila melanogaster.

Lung·2026
Same author

Extracellular stressors change BBSome expression of benign mesothelial and primary pleural mesothelioma cells and affect cell adhesion and migration.

Physiological reports·2026
Same author

The evolving field of nephrology: what comes next? A report from the European Renal Association Scientific Advisory Board.

Clinical kidney journal·2026
Same author

Analysis of Phosphate Transporters in Peritoneal Cells and Tissues and Their Transport Kinetics In Vitro.

International journal of molecular sciences·2026
Same author

Deep secretome analysis reveals the effects of LiCl on fibroangiogenic remodeling in coculture and mouse models of peritoneal dialysis.

Science signaling·2026
Same author

Red Blood Cell Distribution Width and Neutrophil-to-Lymphocyte Ratio as Markers of Cardiovascular Disease and Vascular Calcification in Chronic Kidney Disease: A Large Cohort Study.

Metabolites·2026

Related Experiment Video

Updated: Jan 3, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.0K

Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.

Rajesh M Jagirdar1, Andreas Bozikas1, Sotirios G Zarogiannis2,3

  • 1Division of Nephrology and Hypertension, 1st Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

International Journal of Molecular Sciences
|November 21, 2019
PubMed
Summary
This summary is machine-generated.

Encapsulating peritoneal sclerosis (EPS) is a severe complication of peritoneal dialysis (PD). Early risk factor assessment, diagnosis, and intervention are crucial for managing this condition and improving patient outcomes.

Keywords:
encapsulating peritoneal sclerosisfibrosisperitoneal dialysis

More Related Videos

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage
04:25

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage

Published on: April 28, 2022

2.2K
Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.9K

Related Experiment Videos

Last Updated: Jan 3, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.0K
A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage
04:25

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage

Published on: April 28, 2022

2.2K
Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.9K

Area of Science:

  • Nephrology
  • Gastroenterology
  • Pathology

Background:

  • Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term peritoneal dialysis (PD).
  • Its incidence rises with PD duration and is linked to factors like bioincompatible solutions, high transporter status, and inflammation.
  • EPS can persist even after switching to hemodialysis (HD) or kidney transplantation.

Purpose of the Study:

  • To review the causative factors, clinical presentation, diagnostic methods, and therapeutic strategies for Encapsulating Peritoneal Sclerosis (EPS).
  • To highlight the importance of early diagnosis and intervention in managing EPS.

Main Methods:

  • Review of existing literature on Encapsulating Peritoneal Sclerosis (EPS).
  • Analysis of causative factors, clinical symptoms, diagnostic findings (radiological, macroscopic, microscopic), and treatment outcomes.
  • Evaluation of empirical and experimental therapeutic approaches.

Main Results:

  • EPS is associated with chronic PD, bioincompatible solutions, high transporter status, peritonitis, and inflammation.
  • Clinical signs include intestinal obstruction and ultrafiltration failure.
  • Pathological findings reveal a fibrotic and calcified peritoneum.
  • Current treatments like corticosteroids and tamoxifen are empirical; immunosuppressants and agents studied in animals show potential.
  • High mortality rates persist despite interventions.

Conclusions:

  • Managing EPS requires careful consideration of risk factors, prompt PD discontinuation, and timely therapeutic interventions.
  • Despite empirical evidence, early diagnosis and treatment are mandatory to improve outcomes for this devastating complication.
  • Further research into effective treatments is warranted.